Coenzyme Q10 in Huntington's Disease (HD)

Inclusion Criteria

• •To be eligible for enrollment into this study, subjects must meet the following eligibility criteria within 28 days prior to randomization:
• •Subjects must have clinical features of HD and a confirmed family history of HD, OR a CAG repeat expansion ≥ 36.
• •TFC \> 9.
• •Must be ambulatory and not require skilled nursing care.
• •Age ≥ 16 years.
• •Women must not be able to become pregnant (e.g., post menopausal, surgically sterile or using adequate birth control methods for the duration of the study).
• •If psychotropic medications are taken (e.g., anxiolytics, hypnotics, benzodiazepines, antidepressants), they must be at a stable dosage for four weeks prior to randomization and should be maintained at a constant dosage throughout the study, as possible. (Note: stable dosing of tetrabenazine is allowable.) Any changes to these medications mandated by clinical conditions will be systematically recorded and the subject will be permitted to remain in the trial.
• •Able to give informed consent and comply with trial procedures
• •Able to take oral medication.
• •May be required to identify an informant or caregiver who will be willing and able to supervise the daily dosing of study medications and to maintain control of study medications in the home.
• •A designated individual will be identified by the subject to participate in the ongoing consent process should the subject's cognitive capacity to consent become compromised during participation in the study.